Patient Population
Between September 2020 and October 2021, we conducted a prospective, single-center study including 103 patients with mitral valve prolapse (MVP) and 40 healthy age- and sex-matched control subjects. Age<18, history or symptoms of coronary artery disease, heart valve disease with a more-than-mild severity, reduced ejection fraction (EF≤50), elevated systolic pulmonary arterial pressure (SPAP) at rest (>50 mm Hg), heart failure and/or atrial fibrillation were regarded as the exclusion criteria. The control group comprised age- and gender-matched healthy subjects. Medical history was obtained for all participants, and each subject underwent physical examination including body surface area (BSA). The local ethics research committee approved the protocol, and each subject signed an informed consent form. The study complies with the Declaration of Helsinki.